Current stock page

Catalysts

ROIV Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 4, 2026

ROIV

Catalysts
Roivant Sciences Ltd.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 4/10
Low Priority
In Line With Peers
Score data as of Sep 4, 2026
Last price
$34.93
+$0.52 (+1.51%)
Latest market quote
Momentum40
Value34
Quality60
Risk Resilience69
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 9, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 49/100

Momentum 40/100 and sentiment before the next covered event.

Recent coverage
0 articles

Updated · Sentiment not scored

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 40/100AIQ Edge 4/10 In Line With Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
+3.9%
Across covered historical reports
Latest result
-10.1%
Aug 6, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 6, 2026-$0.30-$0.33-10.1%$2.06M$1.44M
May 20, 2026-$0.29-$0.28+3.5%$3.41M$2.52M
Feb 6, 2026-$0.30-$0.24+19.9%$5.08M$2M
Nov 10, 2025-$0.32-$0.20+36.9%$5.62M$1.57M
Aug 11, 2025-$0.25-$0.25-0.8%$7.3M$2.17M
May 29, 2025-$0.26-$0.29-10.1%$54.07M$7.57M
Feb 10, 2025-$0.25-$0.23+9.0%$5M$9.02M
Nov 12, 2024-$0.25-$0.29-17.4%$45.92M$4.48M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
1
Hold
12-month analyst target
$40.00
+14.51% versus current price
Based on 5 analyst observations. Targets are estimates, not predictions.
Low target
$36.00
+3.06% vs latest price
Average target
$40.00
+14.51% vs latest price
High target
$42.00
+20.24% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 9, 2026

Next known earnings or reporting date.

EPS estimate-$0.41

Current analyst expectation for the upcoming report.

Revenue estimate$3.92M

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score40

Where event reaction would show up first.

AIQ score49/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
5
Average target
$40.00
Target upside
14.51%
Target range
$36.00 - $42.00
90-day revisions
-120

News And Sentiment

Recent company coverage, scored where source sentiment is available.

No recent articles have a scored sentiment label.
Positive
0
Neutral
0
Negative
0

No recent company-specific news is available.

Open full news and sentiment

ROIV Catalysts FAQ

What are the next catalysts for ROIV stock?

ROIV's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ROIV stock?

Upcoming events that could move ROIV include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ROIV's next earnings report affect the stock?

ROIV's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ROIV stock higher?

ROIV could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ROIV stock?

ROIV could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.